As a fellowship director, Mary Chamberlin, MD, needed to adopt a new mind-set when training her fellows from low-income countries.
Advanced sequencing techniques have revolutionized the understanding of how cancer has developed and enabled treatment selection based on genomic characterization of the tumor.
Neeraj Agarwal, MD, discusses his preferred sequencing strategies for treating patients with kidney cancer, and ongoing immunotherapy research in the field.
Arun S. Singh, MD, discusses current and emerging treatment strategies for patients with uterine leiomyosarcoma and other sarcomas.
The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.
The European Commission has granted blinatumomab full marketing authorization for the treatment of adult patients with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia, according to Amgen, the developer of the anti-CD19 immunotherapy.
Christopher R. Flowers, MD, MS, shares insights about the POLARIX trial in diffuse large B-cell lymphoma.
Cryoablation may help men whose prostate cancer recurs after radiation therapy avoid or delay retreatment with androgen deprivation therapy.
Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.
The combination of neratinib and T-DM1 induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer.